2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Transplantation, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Natural Language Processing, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Thromboembolism, Bone Marrow Failure Syndromes, Genetic Disorders, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, MDS, MPN, CML, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2823 Asciminib vs ATP-competitive tyrosine kinase inhibitors: Comparative cardiovascular outcomes in chronic myeloid leukemia: A trinetx study

Shaniah Holder, MD, Talia Alexander2, Amir Kamran, MD3
1 Charleston Area Medical Center, Charleston, West Virginia, United States
2 Charleston Area Medical Center, Charleston, West Virginia, United States
3 Charleston Area Medical Center, Charleston, West Virginia, United States
Introduction 
Tyrosine Kinase Inhibitors (TKI) have significantly increased survival outcomes in chronic myeloid leukemia (CML); however, cardiovascular (CV) toxicities have emerged as a major source of morbidity among patients on TKI therapy. Asciminib is the first inhibitor to specifically target the ABL Myristoyl Pocket (STAMP) and differs mechanistically from the adenosine triphosphate (ATP)-competitive BCR-ABL inhibitors. Some clinical trials suggest a potentially favorable safety profile; however, real-world data on CV outcomes remain limited. A multi-center real-world data network such as TriNetX enables more comprehensive assessment across multiple institutions.  

Objective 
To compare the incidence of a modified major adverse cardiovascular events (MACE) composite, defined as acute ischemic heart disease and ischemic stroke/transient ischemic attack (TIA), as well as other CV outcomes (peripheral arterial disease, heart failure, coronary artery disease (CAD) and coronary revascularization, cardiac arrhythmias, and statin exposure), among adults with CML treated with asciminib versus ATP-competitive TKIs using the TriNetX real-world database. 

Methods 
We performed a retrospective cohort study using the TriNetX Research Network to identify adults aged 18 to 89 years with CML diagnosed between January 1, 2021, and January 1, 2026, who received asciminib or an ATP-competitive TKI (imatinib, dasatinib, nilotinib, bosutinib, or ponatinib). Patients with a history of CV disease, or a history of statin use or prior coronary revascularization before TKI initiation were excluded. Patients were 1:1 propensity score matched on age, sex, race, ethnicity, body mass index, smoking status, type 2 diabetes mellitus, hypertension, chronic kidney disease, and prior chemotherapy exposure. Outcomes included acute ischemic heart disease, ischemic stroke or TIA, peripheral arterial disease (PAD), CAD, coronary revascularization, heart failure, cardiac arrhythmias, and statin exposure. Outcomes were evaluated over a 2-year follow-up period. Because TriNetX does not capture cause-specific mortality, MACE was defined as a composite of acute myocardial infarction and ischemic stroke only. Risk ratios (RRs), and 95% confidence intervals (CIs) were calculated for outcome comparisons. Kaplan-Meier analyses with log-rank tests and hazard ratios with 95% CIs were used to evaluate time-to-event outcomes. Statistical significance was defined as p<0.05. 
 
 Results 
A total of 706 patients treated with asciminib and 3,253 treated with ATP-competitive TKIs met inclusion criteria. After 1:1 propensity score matching, 693 patients remained in each cohort with well-balanced baseline characteristics (all standardized mean differences <0.10). Overall, the mean age was 50.7 years, 45.8% of patients were male, 70.6% were white, 66.2% were non-Hispanic, 30.2% had hypertension, 9.1% had diabetes, and 7.3% had chronic kidney disease. There were no significant differences between asciminib and other TKIs for modified MACE (19 vs. 14 events; HR 1.60, 95% CI 0.80–3.20; log-rank p=0.18), CAD (26 vs. 25 events; HR 1.2, 95% CI 0.69–2.08; p=0.51), heart failure (28 vs. 33 events; HR 0.99, 95% CI 0.60–1.64; p=0.97), cardiac arrhythmias (42 vs. 34 events; HR 1.42, 95% CI 0.91–2.24; p=0.12), or statin exposure (7.6% vs. 7.2%; RR 1.05, 95% CI 0.72–1.54). Individual event counts for acute myocardial infarction, ischemic stroke, PAD, and coronary revascularization were too low (≤10 events per group) for statistical analysis in TriNetX. 
 
Conclusion 
In this real-world analysis, asciminib demonstrated a cardiovascular safety profile comparable to ATP-competitive TKIs over 2 years, with no significant differences in modified MACE or other major CV outcomes. Although several individual CV events were too infrequent for robust analysis, these findings support the short-term cardiovascular safety of asciminib in patients with CML. As asciminib continues to be on the market for a longer period of time, the long-term CV risk profile would be better defined in future studies.
Shaniah Holder, MD: No relevant conflicts of interest to declare.